Enveda Market Research Report

Company Overview

• Name: Enveda

• Mission: Enveda aims to give hope to millions around the world by accelerating the discovery of better medicines.

• Founded: 2019

• Founder: Viswa Colluru, PhD

• Key People:

• Viswa Colluru, PhD - Founder & CEO

• Daniel Wee, PhD - Chief of Staff

• August Allen - Chief Technical Officer

• Bigyan Bista, PhD - SVP Business Strategy & Development

• Eswar Bonangi - VP, India Operations

• Hannah Gordon, PhD - Chief Product Officer

• Inhwan Kim, PharmD - SVP Portfolio Strategy & Operations

• José Trevejo, MD, PhD - CMO and Head of Clinical Pipeline Strategy

• Headquarters:

• 5700 Flatiron Parkway, Boulder, CO, USA

• 3rd Floor, Building 3600 - Synergy Square-3, Genome Valley, Hyderabad, India

• Number of Employees: No information is available.

• Revenue: No information is available.

• Industry Contribution: Enveda is known for discovering medicines from natural sources 4X faster than the industry average, utilizing AI-enabled drug discovery platforms.

Products

Drug Discovery Platform

• Description: Enveda's platform deciphers nature's hidden chemistry, allowing drug discovery with unprecedented speed and scale.

• Key Features:

• AI/ML (Artificial Intelligence/Machine Learning): Utilizes AI to analyze the chemical structure of thousands of molecules simultaneously, making it faster and more cost-effective.

• Pipeline: Features molecules like ENV-294 and ESN-X2 catering to disorders such as atopic dermatitis, inflammatory bowel disease, etc.

• Mass Spectrometry and PRISM Model: The platform uses mass spectrometry combined with the PRISM foundation model, enabling chemical identification without isolation.

Featured Medicines

1. ENV-294

• Problem it Solves: Addresses atopic dermatitis, a condition affecting over 10% of the U.S. population.

• Solution Offered: A first-in-class oral medication with a potentially powerful anti-inflammatory mechanism, reducing associated toxicities.

2. ESN-X

• Problem it Solves: Targets inflammatory bowel disease by hitting multiple clinically validated pathways.

• Solution Offered: A gut-preferred, convenient oral medicine with potential for improved safety and efficacy.

Recent Developments

• New Products: Enveda has recently discovered candidate molecules like ENV-294 and ESN-X that are now advancing to clinical trials.

• Platform Updates: Introduction of the PRISM foundation model for chemical identification using AI, thus accelerating the discovery process.

• Partnerships:

• Collaboration with Microsoft to enhance their AI technology for chemistry translation.

• Partnering with the Bill & Melinda Gates Foundation for developing medicines targeting tuberculosis and malaria.

• Funding: Enveda raised $130 million in a Series C funding round.

Overall, Enveda is shaping the future of drug discovery by harnessing natural compounds and leveraging advanced technology for unprecedented medical solutions.